Comparative assessment of Safety and Efficacy of Vortioxetine with Escitalopram in patients with MDD: a randomized, comparative, parallel group, open-label study - MDD= Major Depressive Disorder

Dr Anshul Upadhyay0 sites60 target enrollmentTBD

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Health Condition 1: F339- Major depressive disorder, recurrent, unspecified
Sponsor: Dr Anshul Upadhyay
Enrollment: 60
Status: Completed
Last Updated: 4 years ago

No summary available.

Registry

who.int

Start Date

TBD

End Date

September 30, 2021

Last Updated

4 years ago

Study Type

Interventional

Sponsor

Dr Anshul Upadhyay

•1\.Patients with primary diagnosed depression with MADRS (Montgomeryâ??Ã?sberg Depression Rating Scale) score \>22 and no other concurrent psychiatric disorders at baseline.
•2\.Patients of 18 â?? 60 years of age
•3\.Subjects of either gender
•4\.Subjects willing to give written informed consent.

•1\.Patients with history of substance abuse.
•2\.Patients with two failed previous antidepressant treatments (of at least 6 weeks in duration)
•3\.Patient with any other long\-term treatment like anti\-hypertensive, anti\-diabetic,
•anti\-tubercular
•4\.Patients with neurological disorders (dementia, stroke, seizures), obesity with
•functional impairment, serious or not stabilized organic disorder (neoplastic,
•cardiovascular, pulmonary, uncontrolled diabetes).
•5\.Patients who pose a significant risk of suicide, had a score of 5 on item 10
•(suicidal thoughts) of the MADRS or had made a suicide attempt in the previous 6 months.
•6\.Patients who have received electroconvulsive therapy in the preceding 6 months.